Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
My name is David Emerson. I am a long-term multiple myeloma survivor and MM cancer coach. I live, study and write about multiple myeloma on PeopleBeatingCancer and Beating Myeloma.
Central to the information that PeopleBeatingCancer provides MM patients, survivors and caregivers is what is call “evidence-based” research. The problem with that the term evidence-based, is that conventional oncology applies a different definition to it than I do.
Board certified oncologist can prescribe only FDA approved therapies such as surgery, chemotherapy and radiation. I have always believed that in order to provide the full-spectrum of information necessary to manage their health, I need to provide a broader array of therapies than what the FDA has approved.
Conventional FDA approved therapies can’t cure multiple myeloma. Yet a non-conventional, evidence-based therapy took me from end-stage MM to complete remission, where I have remained, in less than 17 months.
Further, I supplement with a nutraceutical called curcumin. Curcumin has been studied extensively through clinical trials, in vitro and in vivo studies. I believe that MM patients must learn about all types of studies in order to manage their multiple myeloma.
Have you been diagnosed with multiple myeloma? Scroll down the page, post a question or comment and I will reply to you ASAP.
Hang in there,
Epidemiological Study of Multiple Myeloma
“Multiple myeloma (MM), although a rare disease, is the second most common hematologic malignancy. It is found in the spectrum of plasma cell dyscrasias which begins with monoclonal gammopathy of unknown significance to overt plasma cell leukemia and extramedullary myeloma. MM is associated with significant morbidity due to its end-organ destruction…”
Multiple Myeloma Case Study
“While treatment can control the myeloma and improve quality of life for given periods of time, remissions generally become progressively shorter with subsequent relapses, and patients ultimately enter a final refractory phase. To help control symptoms and enhance quality of life, some patients use complementary therapies as an adjunct to their conventional therapy. Here, we describe a myeloma patient who started a daily dietary supplement of curcumin when approaching her third relapse. In the absence of further antimyeloma treatment, the patient plateaued and has remained stable for the last 5 years with good quality of life...”
Clinical Trials Study of Curcumin
” Extensive clinical trials over the past quarter century have addressed the pharmacokinetics, safety, and efficacy of this nutraceutical against numerous diseases in humans. Some promising effects have been observed in patients with various pro-inflammatory diseases including cancer, cardiovascular disease, arthritis, uveitis, ulcerative proctitis, Crohn’s disease, ulcerative colitis, irritable bowel disease, tropical pancreatitis, peptic ulcer, gastric ulcer, idiopathic orbital inflammatory pseudotumor, oral lichen planus, gastric inflammation, vitiligo, psoriasis, acute coronary syndrome, atherosclerosis, diabetes, diabetic nephropathy, diabetic microangiopathy, lupus nephritis, renal conditions, acquired immunodeficiency syndrome, β-thalassemia, biliary dyskinesia, Dejerine-Sottas disease, cholecystitis, and chronic bacterial prostatitis…”
In-Vivo- Test Tube In Animals
“Whether curcumin can overcome chemoresistance and enhance the activity of thalidomide and bortezomib, used to treat patients with multiple myeloma, was investigated in vitro and in xenograft model in nude mice. Our results show that curcumin inhibited the proliferation of human multiple myeloma cells regardless of their sensitivity to dexamethasone, doxorubicin, or melphalan..”
In-Vitro- Test Tube
“Results- The research within the last several years in vitro and in vivo (animal models) showed that curcumin can sensitize cancer cells to different chemotherapeutic agents that are commonly used for Multiple Myeloma treatment. Curcumin up regulates caspase family proteins and down regulates antiapoptotic genes such as Bcl-2 and Bcl-X…
Another property of curcumin is the ability to activate NRF2 and induce the expression of antioxidant enzymes that are shown to protect normal tissue and organs during chemotherapy…